<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22132">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02818712</url>
  </required_header>
  <id_info>
    <org_study_id>IPF: HRQL, comorb and biomark</org_study_id>
    <nct_id>NCT02818712</nct_id>
  </id_info>
  <brief_title>Health-related Quality of Life and Comorbidities in Danish Patients With Idiopathic Pulmonary Fibrosis - a Nationwide Follow-up</brief_title>
  <official_title>Health-related Quality of Life and Comorbidities in Danish Patients With Idiopathic Pulmonary Fibrosis - a Nationwide Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Copenhagen University Hospital, Gentofte</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a high mortality.
      Health-related quality of life (HRQL) is impaired in patients with IPF. Little is known
      about the properties of recently developed HRQL questionnaires and about the longitudinal
      changes in HRQL, including factors with an impact on HRQL. Comorbidities have an impact on
      patients with IPF, but reports differ in incidence and prevalence. The impact of
      comorbidities on HRQL and disease progression has only been studied sparsely. Also, the
      association between biomarkers and disease progression need to be examined further.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Change in St. George's Respiratory Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Baseline, 2 weeks, 6 months, 12 months</time_frame>
    <description>Change in St. George's Respiratory Questionnaire, IPF-specific</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Baseline, 2 weeks, 6 months, 12 months</time_frame>
    <description>Changes in King's Brief Interstitial Lung Disease questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and type of comorbidities</measure>
    <time_frame>Baseline</time_frame>
    <description>Prevalence of comorbidities at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and type of comorbidities</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Incidence of comorbidities after 6 and 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lung function tests</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Change in forced vital capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function tests</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Change in diffusion capacity for carbon monoxide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk test</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Change in 6-minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression in serum/plasma biomarker levels</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Increase or decrease in serum/plasma biomarker levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Change in Short Form 36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Changes in University of California San Diego Shortness Of Breath Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Change in interstitial changes on high resolution CT-scan (HRCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Changes in number of acute exacerbations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Changes in use of supplementary oxygen</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Patients with IPF</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and EDTA-plasma is collected from all patients at 0, 6 and 12 months.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Incident and prevalent patients with IPF in Denmark.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A clinical diagnosis of IPF

          2. Signed informed consent

        Exclusion Criteria:

          1. Clinical, radiological or histological findings inconsistent with a diagnosis of IPF

          2. Inability or unwillingness to adhere to the study

          3. Active on lung transplantation list
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas S Prior, MD</last_name>
    <email>thbjer@rm.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aarhus University Hosptial</name>
      <address>
        <city>Aarhus C</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas S Prior, MD</last_name>
      <email>thbjer@rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nils Hoyer, MD</last_name>
      <email>nils.hoyer@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesper R Davidsen, Consultant, PhD</last_name>
      <email>jesper.roemhild.davidsen@rsyd.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 25, 2016</lastchanged_date>
  <firstreceived_date>June 15, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
